叮噹健康(09886.HK)中期總收入23.27億元 同比增長2.6%
格隆匯8月22日丨叮噹健康(09886.HK)發佈公吿,截至2025年6月30日止六個月,公司總收入為人民幣2,326.9百萬元,同比增長2.6%。總收入同比增加,得益於公司優化城市佈局,聚焦和深耕優勢區域,將北京、上海、深圳等城市建設成「居民最佳健康服務入口」,積極拓展並加密佈局當地智慧藥房網絡,帶來業務較好增長。此外,公司在藥品及商品佈局方面,提升供應鏈服務水平,整體經營效率提升顯著。
截至2025年6月30日止六個月,公司的淨虧損縮減至人民幣52.0百萬元,經調整淨虧損至人民幣5.8百萬元,如撇除匯兑虧損淨額人民幣4.1百萬元,虧損金額將進一步收窄至人民幣1.7百萬元。虧損收窄與業績改善,得益於毛利率提升至35.0%,同比增加1.9個百分點;同時,精細化運營與持續降本增效獲得成效,盈利能力改善顯著。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.